Related Experiment Video
Updated: Aug 6, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Emerging antibody-drug conjugates in metastatic castration-resistant prostate cancer
Charles B Nguyen1, Zachery R Reichert2
1Department of Medical Oncology & Therapeutics Research, City of Hope Orange County, Irvine, CA.
Abstract:
Despite recent advances in therapies, metastatic castration-resistant prostate cancer (mCRPC) remains incurable with poor prognosis in which novel, more effective treatments are urgently needed. Antibody-drug conjugates (ADCs) are a novel class of agents comprised of a monoclonal antibody directed against a cell surface target of interest that delivers a cytotoxic payload through a cleavable linker. While they have achieved tremendous success in other genitourinary cancers such as urothelial cancer, ADCs have promising activity in mCRPC. In this review, we will provide a high-level overview of ADCs and associated cell surface targets being investigated in mCRPC.
Insights
Metastatic castration-resistant prostate cancer (mCRPC) needs new treatments. Antibody-drug conjugates (ADCs) show promise for mCRPC by targeting cancer cells with potent drugs.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) presents a significant clinical challenge with limited curative options.
- Novel therapeutic strategies are essential to improve outcomes for patients with advanced prostate cancer.
Purpose of the Study:
- To review the emerging role of antibody-drug conjugates (ADCs) in treating mCRPC.
- To provide an overview of ADCs and their potential cell surface targets in mCRPC.
Main Methods:
- Literature review of current research on ADCs in mCRPC.
- Analysis of ADC mechanisms of action and target identification.
Main Results:
- ADCs have demonstrated significant activity in other genitourinary cancers.
- Specific cell surface targets are being investigated for ADC development in mCRPC.
Conclusions:
- ADCs represent a promising therapeutic class for mCRPC.
- Further investigation into ADCs and their targets is warranted for clinical application.
